Ardelyx Shares Climb 26% as IBSRELA 2024 Sales Seen at $140M-$150M
$Ardelyx(ARDX.US$ shares climbed 26% after the biopharmaceutical company said it expects $140 million and $150 million in full-year 2024 U.S. net product sales revenue for IBSRELA, a treatment for irritable bowel syndrome with constipation.
The company forecast IBSRELA to bring in more than $1 billion in annual net product sales at its peak, according to its press release on Monday. It also said it expects to generate $2.5 million in product sales of XPHOZAH in the first quarter of commercialization of the treatment designed to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis.
In 2024, the company said it will continue to invest to support future realization of the full potential for IBSRELA, including the expansion of its sales team, additional promotional programming and omnichannel digital capabilities, increased sampling availability, and expanded support provided by the ArdelyxAssist patient services program.
- Luzi Ann Santos | moomoo News
Disclaimer: Moomoo Technologies Inc. is providing this content for information and educational use only.
Read more
Comment
Sign in to post a comment
Moomoo Official Account
Chasing hot stocks
41KFollowers
15Following
34KVisitors
Follow